1d:I[2890,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1e:I[1318,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1f:T5b3,

We’ve spent a lot of time on this show talking about the potential mental health risks and benefits of experiences occasioned by psychedelic medicines. But how do scientists and clinicians know if and to what extent a psychedelic experience is helpful or harmful? Well, we measure it.
In today’s episode of the Psychedelic Therapy Frontiers podcast, we discuss the various ways that scientists and clinicians measure the psychedelic experience and the mental health outcomes of such an experience. We review a few popular questionnaires, discuss brain imaging studies, explore the limitations of these measurement tools, and much more.
For those of you who are new to the show, welcome! Psychedelic Therapy Frontiers is brought to you by Numinus and is hosted by Dr. Steve Thayer and Dr. Reid Robison.

Learn more about our podcast at https://numinus.com/podcast/
Learn more about psychedelic therapy training opportunities at https://numinus.com/training/
Learn more about our clinical trials at https://www.numinus.com/clinical-trials
Learn more about Numinus at https://numinus.com/

Email us at ptfpodcast@numinus.com

Follow us on Instagram:
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/numinushealth/

‌

Episode description

Measuring the psychedelic experience

Episode description